Literature DB >> 18285818

Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib.

Ylian S Liem1, Lars Bode, Hudson H Freeze, Frank Wg Leebeek, Adrienne Am Zandbergen, Jh Paul Wilson.   

Abstract

BACKGROUND: A 22-year-old female presented with edema, diarrhea, hypoalbuminemia and pancytopenia. She had previously been diagnosed with congenital disorder of glycosylation type Ib, and had a history of congenital hepatic fibrosis, portal hypertension and esophageal varices. In the past she had refused mannose therapy because of associated diarrhea and abdominal pain. INVESTIGATIONS: Laboratory examinations, abdominal ultrasonography, bacterial and viral cultures of blood, urine and stools, double-balloon enteroscopy and fecal excretion test using 51Cr-labeled albumin. DIAGNOSIS: Protein-losing enteropathy. MANAGEMENT: Infusion of albumin followed by intravenous and subcutaneous therapy with unfractionated heparin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285818     DOI: 10.1038/ncpgasthep1061

Source DB:  PubMed          Journal:  Nat Clin Pract Gastroenterol Hepatol        ISSN: 1743-4378


  13 in total

Review 1.  Liver involvement in congenital disorders of glycosylation (CDG). A systematic review of the literature.

Authors:  D Marques-da-Silva; V Dos Reis Ferreira; M Monticelli; P Janeiro; P A Videira; P Witters; J Jaeken; D Cassiman
Journal:  J Inherit Metab Dis       Date:  2017-01-20       Impact factor: 4.982

2.  MPDU1 regulates CEACAM1 and cell adhesion in vitro and in vivo.

Authors:  Daniel C Bennett; Aurelie Cazet; Jon Charest; Joseph N Contessa
Journal:  Glycoconj J       Date:  2018-04-18       Impact factor: 2.916

Review 3.  Heparan sulfate proteoglycans.

Authors:  Stephane Sarrazin; William C Lamanna; Jeffrey D Esko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 4.  Consensus guideline for the diagnosis and management of mannose phosphate isomerase-congenital disorder of glycosylation.

Authors:  Anna Čechová; Ruqaiah Altassan; Delphine Borgel; Arnaud Bruneel; Joana Correia; Muriel Girard; Annie Harroche; Beata Kiec-Wilk; Klaus Mohnike; Tiffany Pascreau; Łukasz Pawliński; Silvia Radenkovic; Sandrine Vuillaumier-Barrot; Luis Aldamiz-Echevarria; Maria Luz Couce; Esmeralda G Martins; Dulce Quelhas; Eva Morava; Pascale de Lonlay; Peter Witters; Tomáš Honzík
Journal:  J Inherit Metab Dis       Date:  2020-04-21       Impact factor: 4.982

Review 5.  Therapies and therapeutic approaches in Congenital Disorders of Glycosylation.

Authors:  Christian Thiel; Christian Körner
Journal:  Glycoconj J       Date:  2012-09-16       Impact factor: 2.916

6.  Socio-emotional Problems in Children with CDG.

Authors:  K F E van de Loo; L van Dongen; M Mohamed; T Gardeitchik; T W Kouwenberg; S B Wortmann; R J T Rodenburg; D J Lefeber; E Morava; C M Verhaak
Journal:  JIMD Rep       Date:  2013-06-04

Review 7.  Therapeutic approaches in Congenital Disorders of Glycosylation (CDG) involving N-linked glycosylation: an update.

Authors:  Jan Verheijen; Shawn Tahata; Tamas Kozicz; Peter Witters; Eva Morava
Journal:  Genet Med       Date:  2019-09-19       Impact factor: 8.822

8.  SLC39A8 deficiency: biochemical correction and major clinical improvement by manganese therapy.

Authors:  Julien H Park; Max Hogrebe; Manfred Fobker; Renate Brackmann; Barbara Fiedler; Janine Reunert; Stephan Rust; Konstantinos Tsiakas; René Santer; Marianne Grüneberg; Thorsten Marquardt
Journal:  Genet Med       Date:  2017-07-27       Impact factor: 8.822

Review 9.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

10.  Liver Involvement in Congenital Disorders of Glycosylation and Deglycosylation.

Authors:  Patryk Lipiński; Anna Bogdańska; Piotr Socha; Anna Tylki-Szymańska
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.